Journal
JOURNAL OF NATURAL PRODUCTS
Volume 70, Issue 3, Pages 402-406Publisher
AMER CHEMICAL SOC
DOI: 10.1021/np060592k
Keywords
-
Funding
- NCI NIH HHS [CA 94426, R01 CA094426-10, R01 CA094426] Funding Source: Medline
- NIAID NIH HHS [K02 AI051689, R01 AI051687, AI 51687, K02 AI051689-05] Funding Source: Medline
- NIGMS NIH HHS [T32 GM 08505, T32 GM008505] Funding Source: Medline
Ask authors/readers for more resources
Zorbamycin (1, ZBM) is a glycopeptide antitumor antibiotic first reported in 1971. The partial structures of 1 were speculated on the basis of its acid hydrolysis products, but the structure of the intact molecule has never been established. The low titer of 1 from the wild-type strain, combined with its acid-instability, has so far hampered its isolation. By random mutagenesis of Streptomyces flavoviridis ATCC21892, a wild-type producer of 1, with UV irradiation, two high-producing strains of 1, S. flavoviridis SB9000 and SB9001, were isolated. Under the optimized fermentation conditions, these two strains produced about 10 mg/L of 1, which was about 10-fold higher than the wild-type ATCC21892 strain, as estimated by HPLC analysis. Finally, 1 was isolated as both a 1-Cu complex and Cu-free molecule, and the intact structure of 1 was established on the basis of a combination of mass spectrometry and H-1 and C-13 NMR spectroscopic analyses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available